Picture of IDEXX Laboratories logo

IDXX — IDEXX Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

IDEXX raises annual forecasts on strong pet diagnostics demand

May 5 (Reuters) - IDEXX Laboratories IDXX.O raised its forecasts for annual revenue and profit on Tuesday after first-quarter revenue topped Wall Street estimates, helped by demand for its veterinary diagnostics products.

Shares of the Westbrook, Maine-based company were up more than 3% in premarket trading.

The company now expects 2026 profit in the range of $14.45 to $14.90 per share, compared with its prior forecast of $14.29 to $14.80 per share. Analysts, on average, were expecting $14.51 per share, according to LSEG data.

IDEXX also raised its 2026 revenue forecast to $4.68 billion to $4.76 billion, from its earlier range of $4.63 billion to $4.72 billion.

IDEXX said the higher forecast reflected stronger expected performance in Companion Animal Group Diagnostics recurring revenue and modestly improving clinical visit trends.

The company reported first-quarter revenue of $1.14 billion, above analysts' estimate of  $1.11 billion.

"IDXX's 1Q results look quite strong to us, with the underlying building blocks of the beat potentially enough to help mitigate macro headwinds going forward," Leerink Partners analyst Daniel Clark said.

Quarterly profit per share rose 17% to $3.47, compared to $2.96 per share a year earlier.

Revenue from the Companion Animal Group, IDEXX's largest business, rose 15% to $1.05 billion.

 (Reporting by Kunal Das in Bengaluru; Editing by Maju Samuel)

 ((Kunal.Das2@thomsonreuters.com;))

Recent news on IDEXX Laboratories

See all news